Elanco finalizes Posilac acquisition

In August Elanco, a division of Eli Lilly and Company, announced its intent to acquire Posilac, a supplement for dairy cows, from Monsanto. Today, Elanco finalized the deal.

The acquisition includes complete worldwide rights, a state-of-the-art manufacturing facility in Georgia and product-support operations.

“Our entire Elanco dairy team is thrilled to be the steward of this vital technology, and already is hard at work to make this business transition seamless for the dairy producers who use Posilac,” said Roy Riggs, director of Elanco’s dairy business unit. “Importantly, with this acquisition, Elanco is strongly committed to collaborating with and providing choice to the dairy food chain.”

Producers can continue to work directly with their Posilac representatives for product support and inquiries. The same convenient toll-free number 800-233-2999 will remain available for placing orders and asking additional questions. Producers using other Elanco products may continue to buy those items from their current animal health suppliers.


DHM Logo-Black-CL
Read Next
With more than half of producers lacking a succession plan and 25% set to retire by 2031, the dairy industry faces a succession cliff that threatens to erase family legacies and vital operational knowledge.
Get News Daily
Get Market Alerts
Get News & Markets App